ProCE Banner Series

Redefining Myelofibrosis Care: Treatment Advances & Key Considerations for Managed Care Professionals

Join us for an interactive, 90-minute, CPE-certified webinar featuring perspectives from pharmacist experts on the latest advances in the care of patients with myelofibrosis including a discussion of the varied roles of pharmacists.

  ACPE-P
Who Should Attend

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists who care for patients with myelofibrosis, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

All Events

Redefining Myelofibrosis Care: Treatment Advances & Key Considerations for Managed Care Professionals

Upcoming Events

April

30

2024

12:00 PM - 1:30 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Justin R. Arnall, PharmD, BCOP

Clinical Coordinator, Hematology
Atrium Health Specialty Pharmacy Service
Charlotte, North Carolina

ProCE Banner Faculty
Victoria R. Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Topics

  • Welcome, Opening Remarks, and Baseline Outcomes Assessment
  • Optimizing Initial Treatment and Recognizing Patterns of Suboptimal Response
    • Case-Based Discussion
  • Navigating Disease Progression or Intolerance to Initial Therapy
  • Managing Common Toxicities Associated With Therapy for MF
    • Case-Based Discussion
  • What’s on the Horizon in MF Treatment?
  • Managed Care Considerations in the Evolving Landscape of Myelofibrosis Treatment
    • Discussion: Pharmacist’s Management Strategies
  • Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Program Goal
The goal of this educational program is to improve managed care pharmacy professionals’ knowledge and competence related to recognizing the clinical implications associated with suboptimal treatment of MF and understanding the unmet needs in care, making evidence-based recommendations based on the latest clinical data surrounding novel and emerging therapies, and developing strategies to support patient-centered care in MF.

Target Audience
The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists who care for patients with myelofibrosis, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Recommend available therapies reflecting a best-practice strategy for first-line treatment of patients with MF based on available data and expert recommendations, considering risk of relapse, molecular features, cytogenetics, and symptom burden

  • Develop evidence-based second-line therapeutic strategies for patients with MF who are relapsed, refractory, or intolerant to prior JAK inhibitor therapy

  • Assess the toxicity profiles of current and emerging MF therapies to collaboratively formulate an adverse event management plan that supports quality of life and continuation of treatment

  • Explain new data on emerging agents for MF to educate colleagues and counsel eligible patients regarding ongoing trial opportunities 

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-24-008-L01-P has been assigned to this live application-based activity (initial release date 04/30/2024). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles. 

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC In partnership with Clinical Care Options, LLC 

Supported by an educational grant from GlaxoSmithKline.